Docket #: S17-409
Compounds targeting phospholipid synthesis to treat cancer and metabolic disease
Disease indication:
Cancer: Renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), lymphoma and potentially other MYC-driven cancer
Drug format: Small molecule compounds, alone or in combination with other chemotherapeutic drugs
Drug class: First-in-class
Target: enzymes in phospholipid metabolic pathway
Research stage and Preliminary data:
The inventors demonstrated that various lipogenesis inhibitors suppress cancer proliferation in human and murine lymphoma lines.
Continued research: The inventors continue to develop SAR for leads.
Background: Previous studies have shown that lipid metabolism is frequently perturbed in cancers. Using desorption electrospray mass spectrometry (DESI-MSI), the inventors showed that phospholipid metabolism is altered.
Mode of action: Inhibiting phospholipid metabolism disrupts cancer metabolism, suppressing cancer proliferation. To date, the inventors have demonstrated results for lymphomas, HCC and RCC.
Advantages
- First-in-class approach with potential for treating a wide range of cancers
- This is a novel target in oncology
Related Links
Patents
- Published Application: WO2019165232
- Published Application: 20210002240
- Issued: 11,702,394 (USA)
Similar Technologies
-
DNA Repair Compounds to Prevent Cancer S10-253DNA Repair Compounds to Prevent Cancer
-
BMP Activators for Treating Bladder Cancer and Other Tumors S13-498BMP Activators for Treating Bladder Cancer and Other Tumors
-
Polyspecific integrin-binding peptide (PIP)-LYTAC for degradation of integrins S20-337Polyspecific integrin-binding peptide (PIP)-LYTAC for degradation of integrins